secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0001437749-24-037689
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma announces PKU GOLIKE trial shows statistically significant metabolic control improvement
--------------------------------------------------------------------------------

- PKU GOLIKE showed statistically significant reduction in blood Phe (P=0.0002) and increase in Tyr (P=0.0113) vs standard substitutes during overnight fasting.
- Average 17.8% reduction in Phe (P=0.0484) and 33.8% increase in Tyr (P=0.0008) from baseline with PKU GOLIKE; standard substitutes led to 27.6% Phe increase.
- Study was randomized crossover in pediatric classical PKU patients at Birmingham Children's Hospital; results to be presented at ACMG 2025.
- Eton expects data to promote adoption of PKU GOLIKE; product is marketed via existing metabolic sales force.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924037689/0001437749-24-037689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924037689/eton20241216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-037689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer